What question did this study set out to answer?

This research aims to evaluate the effectiveness of dacomitinib as a first-line treatment for advanced non-small cell lung cancer (NSCLC) with specific EGFR mutations.

March 2, 2026

View Full Paper

Dacomitinib as a First-Line Therapy for Advanced EGFR-Mutated Non-Small Cell Lung Cancer Without Brain Metastases: A Multicenter Retrospective Observational Study.

Key Points

This research aims to evaluate the effectiveness of dacomitinib as a first-line treatment for advanced non-small cell lung cancer (NSCLC) with specific EGFR mutations.
Multicenter retrospective observational design
Focus on patients with advanced NSCLC and common EGFR mutations
Assessment of progression-free survival (PFS) in relation to clinical features
Dacomitinib showed favorable efficacy and tolerability as first-line therapy
Worse PFS was linked to ECOG performance status ≥ 2
Presence of bone or liver metastases associated with poorer outcomes

Abstract

Dacomitinib demonstrated favorable efficacy and tolerability as a first-line therapy in advanced NSCLC patients with common EGFR mutations (exon 19 deletion or L858R). A baseline ECOG PS ≥ 2 and the presence of bone or liver metastases were significantly associated with worse PFS, suggesting a need for additional therapeutic strategies in these subgroups.

AI से पूछें

Bookmark

View Full Paper

Cite This Study

Hung et al. (Sun,) studied this question.

synapsesocial.com/papers/69a52e04f1e85e5c73bf1555 https://doi.org/https://doi.org/10.1002/cam4.71659

AI से पूछें

Bookmark

View Full Paper